R&D channel feed

A biotech emerges from one Deer­field­'s R&D do­na­tion part­ners

6 years ago

Aca­dia un­veils the pos­i­tive PhI­II it's tak­ing to FDA for ex­pand­ing Nu­plazid's use in psy­chosis

6 years ago

Putting the safe­ty is­sue to bed, Au­rini­a's late-stage lu­pus nephri­tis da­ta shines

6 years ago

Sage's star ex­per­i­men­tal de­pres­sion drug fails the cru­cial MOUN­TAIN study — shares crash

6 years ago

Josh Bilenker and his Loxo crew are tak­ing the reins on on­col­o­gy R&D at Eli Lil­ly, culling the weak and map­ping a new path

6 years ago

Near­ly a year af­ter sur­prise re­jec­tion, Im­munomedics re­turns to FDA

6 years ago

Cell, gene ther­a­py man­u­fac­tur­ing takes cen­ter stage as No­var­tis, Ama­zon join forces

6 years ago

Mer­ck in $1.3B show­down with in­sur­ers over 2017 ran­somware at­tack — Bloomberg

6 years ago

Ea­ger to tout piv­otal win, Omeros how­ev­er keeps key pa­ra­me­ters shroud­ed

6 years ago

As it shops for new deals, Akcea hires for­mer GSK ex­ec as COO

6 years ago
People

An old, con­tro­ver­sial Pfiz­er drug shows mid-stage ef­fi­ca­cy against nar­colep­sy

6 years ago

Bio­gen comes un­der re­newed fire as a lead­ing Alzheimer's ex­pert rais­es se­ri­ous ques­tions about the ad­u­canum­ab da­ta

6 years ago
People

Arde­lyx reach­es the 'cap­stone' in their third-straight pos­i­tive PhI­II – but many ques­tions still linger

6 years ago

Bio­gen boasts PhII win in lu­pus — will any­one turn their head from Alzheimer's to no­tice?

6 years ago

Strug­gling Adap­ti­m­mune gets a boost from the FDA as T cell can­cer drug wins an in­side track at the agency

6 years ago

FDA ush­ers Mer­ck­'s star can­cer drug Keytru­da to­ward an­oth­er key check­point

6 years ago

Neu­ro­crine is beef­ing up its pipeline, splurg­ing $50M on rights to an epilep­sy drug

6 years ago

The race to best treat a dis­ease long con­fused with MS heats up with Roche's PhI­II re­sults

6 years ago

An­a­lyst Bri­an Sko­r­ney goes griz­zly on Bio­gen’s Alzheimer’s ‘hype,’ ‘fear­mon­ger­ing’ and ‘sta­tis­ti­cal mal­prac­tice’

6 years ago

Just days ahead of his big strate­gic re­veal, Sanofi CEO Paul Hud­son lines up a $350M sale

6 years ago

As­traZeneca gains a speedy Imfinzi re­view in race to beat Roche on front­line SCLC

6 years ago

In­sid­er ac­count of UCB’s $2.1B deal to buy Ra Phar­ma spot­lights a dis­ci­plined M&A strat­e­gy — and $120M wind­fall for ex­ecs

6 years ago

Ko­re­an biotech’s shares soar for a 'best of ES­MO' award it nev­er re­ceived

6 years ago

Roche's Xofluza may give rise to re­sis­tant strains, rais­ing fears of a 'worst case sce­nar­i­o'

6 years ago
First page Previous page 220221222223224225226 Next page Last page
A service from the Financial Times